Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03555617 · ClinicalTrials.gov registry record · Phase 1

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

A Phase 1 study, sponsored by Theravance Biopharma.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target

NCT03555617 is a Phase 1 study that has completed, run by Theravance Biopharma. The registered enrollment target is 36 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03555617, a Phase 1 study, has completed, sponsored by Theravance Biopharma.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target

Study Summary

This is a Phase 1, open-label, 2-cohort, food-effect, DDI, and formulation bridging study.

Interventions

  • DRUG Itraconazole
  • DRUG TD-1473

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2018-06-13
Est. Completion 2018-07-15
Phase Phase 1

Sponsor

Theravance Biopharma

38 total trials

What the Registry Record Tells You About NCT03555617

The ClinicalTrials.gov registry entry for NCT03555617 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.

NCT03555617 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03555617 about?

NCT03555617 is a clinical study titled "Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study". This is a Phase 1, open-label, 2-cohort, food-effect, DDI, and formulation bridging study.

What is the current status of trial NCT03555617?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-06-13. Estimated completion is 2018-07-15.

What interventions are being tested in trial NCT03555617?

The interventions under investigation include: Itraconazole (DRUG), TD-1473 (DRUG).

Who is sponsoring clinical trial NCT03555617?

This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.